Trials / Terminated
TerminatedNCT03444753
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
A Phase I Study of BMS-986299 as Monotherapy and in Combination With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In addition, the ability of study drugs to stimulate an immune response against cancer will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986299 | Specified dose on specified day |
| BIOLOGICAL | Nivolumab | Specified dose on specified day |
| BIOLOGICAL | Ipilimumab | Specified dose on specified day |
Timeline
- Start date
- 2018-04-05
- Primary completion
- 2022-02-14
- Completion
- 2022-02-14
- First posted
- 2018-02-23
- Last updated
- 2022-05-23
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03444753. Inclusion in this directory is not an endorsement.